Indication intelligence, analysis and sector perception

Higher open expected, EU and Asia are up

January 22, 2016 6:38am

While, I am still down for the count due to complications; recovery has been slower than anticipated.

Haven’t been wrong, understand WHY, the time has come to SUBSCRIBE! Can you afford not to?

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors before the sector and markets open. But, who is interpreting that information … get it here!

DOW futures are UP +1.2and NASDAQ futures are UP +1.6%

U.S. stock index futures indicated a higher open on Friday as traders looked to economic data and earnings from some big names.

European stocks rallied on Friday, buoyed by dovish remarks from the European Central Bank (ECB), which signaled further monetary easing as early as March.

Asian markets surged Friday, with major indexes posting over 1 percent gains each, tracking the rally in European and U.S. equities overnight and getting a boost from a slight uptick in oil prices and comments from the European Central Bank (ECB).

Data docket: the Markit manufacturing PMI released at 9:45 a.m. ET, with leading indicators and existing home sales due at 10:00 a.m.

The stem, cell and gene therapy RegMed sector closed POSITIVE on Thursday and Wednesday following a NEGATIVE close on Tuesday as Monday was a holiday and the markets were closed.

Past four (4) days:

· Thursday closed POSITIVE with 16 decliners, 25 advancers and 2 flats

· Wednesday closed POSITIVE with 8 decliners, 34 advancers and 1 flat

· Tuesday closed NEGATIVE with 34 decliners, 9 advancers and 0 flats;

· Last, Monday was the Martin Luther King Jr. holiday;

I'd be careful today as the sector is prone to reverses ... there is a tremendous amount of agita in the stem, cell and gene therapy RegMed sector (SCGT&RM) markets that creates short-term spurts that don’t LAST!

Market and sector movement i.e. inefficiencies or not … can create both opportunity and depreciation to your portfolio.

Manage … risk and don’t manage <perceived> return – it is a losing proposition.

Some of those I-Bank valuations are developed to deceive investors; they are usually one person’s view of their paying/financing client.

When investors think of risk management, they MUST think how to mitigate downside volatility to avoid large portfolio drawdowns and that is only … one part of the equation.

Reiterating, as a solid advocate of the sector, I point-out that truth is stranger than fiction but, regardless of the idiom - “our” universe should be bracing for a grim financial reporting season, notice I didn’t say - earnings.

Sorry, I couldn’t define Friday’s indications … recovery has been slower than anticipated.

Remember, the perils of confusing correlation and causation!

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 55 min ago
RMi Closing Bell: Proof of consequences and expectation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.